

Contents

Chapter 1	Targeted therapy for advanced and metastatic renal cell cancer <i>Parts of this chapter have been published in Discov Med 2010;10:394-405</i>	9
PART I	Efficacy of sunitinib in renal cell cancer	
Chapter 2	Sunitinib for treatment of advanced renal cell cancer: primary tumor response <i>Clin Cancer Res 2008;14:2431-6</i>	37
Chapter 3A	Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery <i>World J Urol 2009;27:533-9</i>	47
Chapter 3B	Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib <i>Acta Oncol 2010;49:520-3</i>	57
Chapter 4	Brain metastases in patients with renal cell cancer receiving new targeted treatment <i>J Clin Oncol 2008;26:152-4</i>	65
Chapter 5	Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib <i>Clin Cancer Res 2011;17:620-9</i>	71
PART II	Side-effects of sunitinib	
Chapter 6	Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer <i>Br J Cancer 2008;99:259-65</i>	85
Chapter 7	Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy <i>Ann Oncol 2007;18:1747-50</i>	95
Chapter 8	Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity <i>J Clin Oncol 2009;27:4406-12</i>	103

PART III	Pharmacodynamics of sunitinib	
Chapter 9	Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib <i>Br J Cancer 2010;102:803-9</i>	115
Chapter 10	Sunitinib-induced hemoglobin changes are related to the dosing schedule <i>J Clin Oncol 2009;27:1339-40</i>	125
Chapter 11	Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib <i>Angiogenesis 2009;12:69-79</i>	131
Chapter 12	Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer <i>Int J Cancer 2011</i>	145
Chapter 13A	Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib <i>Anti-Cancer Drugs 2010;21:439-46</i>	159
Chapter 13B	Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon <i>Ann Oncol 2010;21:1923-4</i>	171
Chapter 14	Summary	177
Chapter 15	Discussion and future perspectives <i>Parts of this chapter have been published in Discov Med 2010;10:394-405 & Target Oncol 2010;5:95-112</i>	185
	Nederlandse samenvatting	209
	Dankwoord	219
	Curriculum vitae	227
	Publications	231